Retatrutide (10mg)

Retatrutide is a next-generation triple-agonist peptide research compound designed to simultaneously target the GLP-1, GIP, and glucagon receptors. This unique mechanism is being extensively investigated for its potential effects on appetite regulation, energy expenditure, glucose metabolism, insulin sensitivity, and body composition.
Recent Phase 3 clinical research has demonstrated some of the most significant weight-loss outcomes ever observed in a metabolic therapy, with participants achieving average body weight reductions approaching 30% while also showing improvements in key cardiometabolic markers, including blood glucose control, blood pressure, lipid profiles, and liver fat content.